Eli Lilly Launches Weight-Loss Drug Mounjaro in India at ₹3,500 per Vial After Regulatory Approval
Eli Lilly Launches Weight-Loss Drug Mounjaro in India
New Delhi, March 23 – Global pharmaceutical company Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro (tirzepatide), in India. The drug has received approval from the Central Drugs Standard Control Organization (CDSCO) and is expected to address the rising prevalence of obesity and type 2 diabetes in the country.
A Potential Game-Changer for Diabetes and Obesity
Mounjaro is a once-weekly injectable medication that works by activating GIP and GLP-1 hormone receptors, helping to regulate blood sugar levels and promote weight loss. Clinical trials have shown significant results, with patients losing an average of 21.8 kg over 72 weeks on the highest dose (15 mg).
According to recent estimates, India has nearly 101 million people living with diabetes, making the introduction of such treatments crucial for public health.
Pricing and Availability in India
Eli Lilly has set the pricing of Mounjaro at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial. The company is also working with healthcare providers, insurers, and policymakers to enhance accessibility and affordability.
Competition in India’s Weight-Loss Market
The launch of Mounjaro is expected to intensify competition in India’s weight-loss drug market. Danish pharmaceutical giant Novo Nordisk plans to introduce its obesity drug, Wegovy, in India by 2026. Meanwhile, leading Indian pharma companies such as Sun Pharmaceutical, Biocon, Zydus Lifesciences, Cipla, Dr. Reddy’s, Lupin, Natco Pharma, Mankind Pharma, and Aurobindo Pharma are developing their own GLP-1 agonists or generic versions of semaglutide to tap into the growing demand.
A Booming Global Market
Analysts predict that the global obesity drug market could reach $150 billion annually by the early 2030s. With India facing a rising burden of lifestyle diseases, the introduction of Mounjaro marks a significant step toward expanding treatment options for patients.
